Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) reports on events occurring on March 31, 2022, and April 4, 2022. The primary event is the entry into a Securities Purchase Agreement (SPA) for a registered direct offering of Senior Secured Convertible Notes. Additionally, the filing includes a Regulation FD disclosure regarding a clinical guideline update for its subsidiary, Lucid Diagnostics Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of Senior Secured Convertible Notes.
- Total Principal Amount: Up to $50,000,000.
- Initial Closing: $27,500,000 in principal amount, expected on or about April 4, 2022.
- Purchase Price: $1,000 for each $1,100 in principal amount (approximately 90.9% of par).
- Estimated Net Proceeds: Approximately $24.4 million from the initial closing and $20.4 million from potential additional closings (assuming full sale), after deducting estimated expenses.
- Interest Rate: 7.875% per annum.
- Maturity: Two years from issuance, subject to extension rights.
- Conversion Price: Initial fixed price of $5.00 per share, subject to adjustments and alternate conversion mechanisms.
- Financial Covenants:
- Available cash must equal or exceed $8,000,000 at all times.
- Debt-to-market capitalization ratio must not exceed 30%.
- Market capitalization must not fall below $75 million.
Material Changes and Agreements
The filing details a material definitive agreement involving significant debt financing. Key structural changes include:
- Amortization: Principal repayment occurs via monthly installments starting six months after issuance, payable in cash (at 115% of the installment amount) or shares (at 100% of the installment amount).
- Security: Notes are secured by all existing and future assets, including 9.99% of the outstanding common stock of Lucid Diagnostics Inc.
- Stockholder Approval: The Company must hold a stockholder meeting by July 31, 2022, to increase authorized shares from 150 million to 250 million to facilitate share issuance upon conversion.
- Break-up Fee: A fee of $1,350,000 is payable to the Investor if the Company fails to complete additional closings or if the Investor cannot deliver a notice to require additional closings by March 31, 2024, due to specific limitations.
- Participation Rights: The Investor receives participation rights in future equity or debt offerings for up to three years.
Outlook, Risks, and Management Commentary
Outlook and Commentary: The Company expects to consummate the initial closing on April 4, 2022. The proceeds are intended to fund operations and growth. The filing also highlights a positive development for its subsidiary, Lucid Diagnostics, noting that updated American College of Gastroenterology guidelines support the use of Lucid's EsoGuard DNA Test for esophageal precancer screening.
Risks and Contingencies:
- Events of Default: Includes failure of key executives (CEO Lishan Aklog and CFO Dennis McGrath) to serve in their roles, breach of covenants, or failure to meet financial thresholds.
- Dilution: Conversion of notes and installment payments may result in significant equity dilution, capped at 19.99% of outstanding shares without stockholder approval.
- Market Conditions: Additional closings are subject to minimum price, volume, and market capitalization thresholds.
- Regulatory: The Company is responding to a proposed Local Coverage Determination by Medicare regarding molecular testing for esophageal precancer.
Key Facts for Investor Verification
- Verify the actual closing date and final net proceeds of the initial $27.5 million tranche.
- Confirm the outcome of the stockholder vote required by July 31, 2022, to increase authorized shares.
- Monitor the Company's compliance with the $8 million minimum cash covenant and the 30% debt-to-market cap ratio.
- Assess the impact of the 7.875% interest rate and monthly amortization payments on future cash flow.
- Review the status of the Medicare Administrative Contractor's Local Coverage Determination regarding Lucid's EsoGuard test.